Opioid Use Disorder Market Research Report By Treatment Type (Medications, Therapies, Counseling), By Administration Route (Oral, Injectable, Transdermal), By Patient Age Group (Adolescents, Adults, Geriatrics), By Setting (Inpatient, Outpatient, Residential) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Global Opioid Use Disorder Market Overview

As per MRFR analysis, the Opioid Use Disorder Market Size was estimated at 6.44 (USD Billion) in 2023.The Opioid Use Disorder Market is expected to grow from 6.67 (USD Billion) in 2024 to 9.8 (USD Billion) by 2035. The Opioid Use Disorder Market CAGR (growth rate) is expected to be around 3.56% during the forecast period (2025 - 2035)

Key Opioid Use Disorder Market Trends Highlighted

The Opioid Use Disorder Market is currently influenced by several crucial trends that underscore the urgent need for effective management strategies and treatment options. One of the key market drivers is the rising prevalence of opioid use disorders, compounded by an increase in prescription opioid misuse and addiction.

Governments around the world are responding to this crisis by implementing various legislative measures aimed at reducing opioid prescriptions and enhancing resources for addiction treatment. Additionally, there has been a notable shift towards integrating mental health services with substance use disorder treatment, promoting a comprehensive approach to care.

This market has a lot of potential for new therapeutics and digital health solutions that can improve patient engagement and intervention strategies. The idea of new pharmacotherapies, like new drugs that work on the root causes of addiction, is becoming more popular.

Also, the growing emphasis on prevention and early intervention gives healthcare providers a way to deal with the crisis before it gets worse. There has been a lot of talk lately about how important it is to teach doctors and nurses about the dangers of prescribing opioids and how to use other methods to manage pain.

This trend is bolstered by collaborative efforts among healthcare workers, lawmakers, and advocacy groups aimed at reducing stigma surrounding addiction and promoting access to treatment. Furthermore, global awareness campaigns continue to play a pivotal role in shaping public perception and policy regarding opioid use disorder, gradually fostering a cultural shift towards recognizing and addressing this critical health issue effectively.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Opioid Use Disorder Market Drivers

Increasing Prevalence of Opioid Use Disorder in Global Populations

The Opioid Use Disorder Market is experiencing substantial growth primarily due to the rising prevalence of opioid use disorder in various regions. Recent reports indicate that approximately 35 million people worldwide suffer from opioid use disorders, as derived from World Health Organization statistics. This alarming number highlights the need for effective treatment and rehabilitation services, significantly influencing market demand.

Additionally, organizations like the United Nations Office on Drugs and Crime have reported a concerning increase in global opioid consumption, which has led to a higher number of opioid-related overdoses and fatalities. For example, the global overdose deaths from opioids have reached over 500,000 annually, creating an urgent need for targeted therapies and interventions, including medication-assisted treatments.

Major healthcare institutions and governments across the globe are responding to this crisis by increasing investments in programs that support individuals suffering from opioid dependency, thus further driving the growth of the Opioid Use Disorder Market.

Expansion of Treatment Programs and Rehabilitation Centers

The expansion of treatment programs and rehabilitation centers globally is a key driver for the Opioid Use Disorder Market. Many countries are recognizing the need to establish comprehensive support systems to combat the opioid crisis. In the United States, for example, the Substance Abuse and Mental Health Services Administration reported a 30% increase in the number of accredited treatment facilities over the last five years. This expansion directly correlates with enhanced access to care for those affected by opioid use disorders.

Furthermore, Global health organizations, including the World Health Organization, are advocating for the integration of opioid use disorder treatments into primary healthcare settings. By enhancing service delivery and increasing awareness about the availability of treatments, these initiatives are expected to not only support recovery but also significantly contribute to the market's growth.

Government Initiatives and Funding for Research and Development

Government initiatives and increased funding for Research and Development in therapies to address opioid use disorder are crucial for the Opioid Use Disorder Market. In recent years, multiple governments have acknowledged the opioid epidemic and have taken steps to boost funding for innovative treatment solutions. For instance, in 2021, the U.S. federal government announced an allocation of $1.5 billion for opioid use disorder programs, aiming to develop new therapies and implement preventive measures.

Such government support reflects a commitment to tackling public health challenges related to opioid dependency and directly influences market dynamics by enabling pharmaceutical companies to innovate and release novel treatments. Moreover, global health organizations are continuously pushing for higher funding to enhance treatment options, which constitutes a vital factor in driving the Opioid Use Disorder Market's progression.

Opioid Use Disorder Market Segment Insights

Opioid Use Disorder Market Treatment Type Insights

The Opioid Use Disorder Market is increasingly recognized for its diverse Treatment Type segmentation, which plays a crucial role in addressing the challenges posed by opioid addiction. In 2024, the market is projected to reach a valuation of 6.67 USD billion, with the Treatment Type segment comprising a substantial portion.

The segment consists of three main categories: Medications, Therapies, and Counseling. Among these, the Medications category is the most significant, valued at 3.5 USD Billion in 2024 and expected to grow to 5.1 USD billion by 2035. This segment is critical as it encompasses various pharmacological interventions that help manage withdrawal symptoms and cravings, thus significantly aiding in recovery.

The Therapies segment, valued at 2.0 USD Billion in 2024 and anticipated to increase to 2.7 USD Billion by 2035, focuses on behavioral and psychological strategies to complement medication use.

These therapeutic interventions are essential in promoting long-term recovery and reducing relapse rates, further highlighting the importance of an integrated treatment approach. On the other hand, the Counseling segment, which starts at 1.17 USD Billion in 2024 and progresses to 1.99 USD Billion in 2035, serves as a fundamental support system, providing individuals with coping strategies and emotional support to navigate their recovery journey. This holistic engagement plays a crucial role in rehabilitation, affirming counseling's status as a necessary component of comprehensive care.

The global landscape for opioid use disorder treatment is driven by an increasing awareness of addiction and a growing emphasis on mental health services. Medical professionals and institutions are recognizing the importance of tailoring treatment plans to individual needs, leading to a rise in integrated approaches that combine medications, therapies, and counseling.

This trend is reflected in the market growth statistics, demonstrating a commitment to addressing the multifaceted nature of opioid addiction as societies seek effective solutions to combat this ongoing crisis. Nevertheless, challenges persist, including stigma associated with addiction treatment and policy barriers, which call for continual adaptation of strategies to optimize treatment outcomes and broaden access to essential services.

Overall, the Treatment Type segment plays a fundamental role in the progression and landscape of the Opioid Use Disorder Market, reflecting both the urgent need for effective interventions and the potential for significant growth in comprehensive treatment strategies.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Opioid Use Disorder Market Administration Route Insights

The Opioid Use Disorder Market has been exhibiting a significant trajectory, with the market expected to reach a valuation of 6.67 USD billion in 2024. Within this market, the Administration Route segment plays a crucial role, offering several methods for delivering treatments.

Among these, the Oral administration route is widely recognized for its convenience, allowing patients to manage their treatment at home effectively. Injectable treatments provide rapid relief and are critical in acute management scenarios, showcasing their importance in clinical settings.

Meanwhile, Transdermal delivery systems distinguish themselves with their sustained release capabilities, catering to patients' needs over extended periods. The Opioid Use Disorder Market statistics highlight how these varied administration routes contribute to a comprehensive approach to treatment, addressing factors such as patient compliance and ease of use.

As the global awareness of opioid use disorder continues to rise, the demand for diverse administration routes remains pivotal in enhancing treatment outcomes, responding to the pressing need for effective management strategies worldwide.

Opioid Use Disorder Market Patient Age Group Insights

The Opioid Use Disorder Market is expected to significantly evolve in the coming years, with an estimated valuation of 6.67 USD billion by 2024. This market is distinctly categorized by Patient Age Group, which constitutes vital dynamics in understanding the overall landscape.

Key demographics include Adolescents, Adults, and Geriatrics, each presenting unique challenges and needs. Adolescents face rising opioid misuse, underscoring the need for preventive interventions, while Adults represent a majority holding in the market, mainly due to higher prescription rates and recreational use.

The Geriatrics demographic is increasingly significant, as aging populations are more susceptible to opioid prescriptions for chronic pain management. Addressing their requirements presents opportunities for tailored recovery programs.

Factors such as increasing awareness of opioid addiction and the need for specialized treatments are driving market growth, though significant challenges, including stigma and healthcare accessibility, remain prominent.

Thus, the Opioid Use Disorder Market segmentation by Patient Age Group reveals critical insights, reflecting both the scale of the issue and the necessity for comprehensive solutions globally.

Opioid Use Disorder Market Setting Insights

The Opioid Use Disorder Market, particularly within the Setting segment, is poised for growth as it adapts to changing healthcare needs. By 2024, the market is projected to be valued at 6.67 billion USD, demonstrating the increasing demand for effective treatment options for opioid use disorder.

This segment encompasses various care environments, each playing a pivotal role in managing the disorder. Inpatient care, often vital for severe cases, provides intensive support and monitoring. Outpatient services offer flexibility, allowing patients to integrate recovery into their daily lives while receiving essential treatment.

Residential programs create a structured environment that promotes recovery by offering support and a community approach. Together, these settings provide comprehensive treatment options that address diverse patient needs, reflecting current trends towards personalized care strategies in the Opioid Use Disorder Market.

The growing emphasis on tailored approaches is driven by increasing awareness of mental health issues and the need for accessible treatment solutions, creating significant opportunities within each care environment as the industry adapts to combat this ongoing public health crisis effectively.

Opioid Use Disorder Market Regional Insights

The Opioid Use Disorder Market is showing significant regional variations in its valuation and growth prospects. In 2024, the market is valued at approximately 6.67 USD billion, with North America dominating this landscape at 3.5 USD Billion, making it the largest region by a considerable margin.

This dominance is attributed to a high prevalence of opioid use, which drives the demand for treatment options. Europe follows with a valuation of 2.0 USD billion, highlighting its importance in the Opioid Use Disorder Market revenue, where various initiatives are aimed at tackling opioid misuse.

In South America, the market is valued at 0.5 USD billion, reflecting a growing need for awareness and treatment solutions, but it still lags compared to other regions. The Asia Pacific region, valued at 0.95 USD billion, is witnessing increased focus on addressing opioid dependence, indicating a potential for future growth.

Meanwhile, the Middle East and Africa exhibit a valuation of 0.72 USD billion, suggesting that despite lower current figures, there remains a significant opportunity for market expansion driven by rising healthcare initiatives and increasing access to treatment.

Overall, these regional insights illustrate the varied landscape and evolving challenges and growth drivers within the Opioid Use Disorder Market segmentation.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

Opioid Use Disorder Market Key Players and Competitive Insights

The Opioid Use Disorder Market is a critical area in healthcare, reflecting a significant challenge that has arisen from the widespread use of opioids. With rising addiction rates across various demographics, market players are continuously innovating and adapting their strategies to address this pressing issue. The competitive landscape is characterized by pharmaceutical firms focusing on developing effective treatment options and prevention strategies, including medications such as buprenorphine and methadone.

Additionally, companies are increasingly pursuing partnerships and collaborations to enhance their research capabilities and overcome regulatory challenges associated with opioid-related therapies. The market is evolving, placing emphasis on patient-centric approaches that consider the mental health aspects of opioid use disorder and the importance of comprehensive treatment plans that may incorporate behavioral therapies alongside pharmacological interventions.

Merck is a significant player in the Opioid Use Disorder Market, leveraging an established reputation and extensive research capabilities to develop innovative treatment options. The company is recognized for its strong commitment to addressing public health issues associated with opioid misuse and has invested substantially in clinical research to deliver safe and effective therapies. Merck's prominent position allows it to influence market trends and collaborate with various stakeholders, including healthcare providers and government entities, to optimize treatment access.

The company's ability to engage in strategic partnerships enhances its presence in the market, fostering the development of comprehensive solutions aimed at alleviating the burden of opioid use disorder. Merck's strengths lie in its rigorous approach to product development and its expansive network, ensuring that it maintains a competitive edge in a rapidly evolving landscape.

Mylan also plays a vital role in the Opioid Use Disorder Market, offering a variety of generic and specialty medications aimed at treating addiction. The company is recognized for its diverse portfolio, which includes key products such as buprenorphine formulations used for opioid dependence. Mylan has been actively enhancing its market presence through strategic mergers and acquisitions that expand its reach and capabilities in the healthcare sector, positioning itself as a robust competitor.

Its strengths include a commitment to broadening access to effective therapies in underserved regions and a focus on affordability, which is crucial in addressing the socioeconomic aspects of opioid use disorder. Mylan’s strategic initiatives emphasize the importance of building partnerships to strengthen its distribution networks globally, thus improving the delivery of its products to those in need.

Key Companies in the Opioid Use Disorder Market Include

• Merck


• Mylan


• Pfizer


• Alkermes


• Indivior


• Noven Pharmaceuticals


• Catalent


• AstraZeneca


• GSK


• Eli Lilly


• Johnson & Johnson


• Teva Pharmaceutical


• Braeburn Pharmaceuticals

Opioid Use Disorder Market Developments

The Opioid Use Disorder Market is still seeing big changes as of July 2025, especially in terms of new treatment options and changes to the rules. Companies like Pfizer, Alkermes, and Indivior are at the forefront of the fight against opioid dependence by adding extended-release formulations and other delivery methods to their product lines. Indivior has especially strengthened its position in the market with products like Sublocade, which got more support for clinical use in 2023.

The opioid crisis has made the need for new ideas even greater, which has led research institutions and pharmaceutical companies to speed up their development efforts. Viatris (formerly Mylan) helps with generic formulations, but companies like Merck don't have much direct involvement in OUD-specific therapeutics. In addition, Reckitt Benckiser left this market after selling Indivior in 2014.

There were reports in late 2023 that more money was being put into research on alternatives to opioids, but Eli Lilly has not yet bought a biotech company in this field. Still, the market has been steadily growing, thanks to more awareness, government-funded programs, and new ways of helping people recover. Partnerships between drug companies and research institutions are still very important for developing new ways to treat the global opioid epidemic.

Opioid Use Disorder Market Segmentation Insights

• Opioid Use Disorder Market Treatment Type Outlook
  
  
  
  • Medications
  
  
  • Therapies
  
  
  • Counseling
  
  
  
  

• Opioid Use Disorder Market Administration Route Outlook
  
  
  
  • Oral
  
  
  • Injectable
  
  
  • Transdermal
  
  
  
  

• Opioid Use Disorder Market Patient Age Group Outlook
  
  
  
  • Adolescents
  
  
  • Adults
  
  
  • Geriatrics
  
  
  
  

• Opioid Use Disorder Market Setting Outlook
  
  
  
  • Inpatient
  
  
  • Outpatient
  
  
  • Residential
  
  
  
  

• Opioid Use Disorder Market Regional Outlook
  
  
  
  • North America
  
  
  • Europe
  
  
  • South America
  
  
  • Asia Pacific
  
  
  • Middle East and Africa
  
  
  
  

Report Attribute/Metric	Details
Market Size 2023	6.44 (USD Billion)
Market Size 2024	6.67 (USD Billion)
Market Size 2035	9.8 (USD Billion)
Compound Annual Growth Rate (CAGR)	3.56% (2025 - 2035)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Merck, Mylan, Pfizer, Alkermes, Indivior, Noven Pharmaceuticals, Catalent, AstraZeneca, GSK, Eli Lilly, Johnson & Johnson, Teva Pharmaceutical, Braeburn Pharmaceuticals
Segments Covered	Treatment Type, Administration Route, Patient Age Group, Setting, Regional
Key Market Opportunities	Rising demand for innovative treatments, Increased investment in research funding, Expansion of telehealth services, Growth in educational programs, and enhanced collaboration with governments
Key Market Dynamics	Rising prevalence of opioid addiction, increasing government initiatives, growing awareness about treatment, advancements in treatment modalities, emergence of telehealth solutions
Countries Covered	North America, Europe, APAC, South America, MEA